About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce



SHANGHAI, Mar 18, 2025 - (ACN Newswire) - On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai's Industry and Commerce was brought to a successful conclusion. Dr. Li Chen, the founder and CEO of Hua Medicine, was awarded the title of "A Leading Figure in Shanghai's Industry and Commerce" for his outstanding contributions and innovative leadership in the field of biomedicine. He also gave a speech representing the leading figures at the ceremony. 

(Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce)

The initiative to select the leading figures in Shanghai's industry and commerce dates back to 2006. It is jointly sponsored by the Shanghai Federation of Industrial Economics and the Shanghai Federation of Economic Organizations, and jointly organized by the Shanghai General Chamber of Commerce and the Shanghai Enterprise Confederation. The selection aims to encourage industrial and commercial leaders and entrepreneurs to work hard, and make new contributions to Shanghai's cultivation and development of new quality productivity, and the acceleration of the construction of the "Five Centers" and the modern industrial system. A total of 67 entrepreneurs from various industries were selected. 

With more than 30 years of experience in new drug R&D and management, Dr. Li Chen returned to Shanghai from the U.S. in 2004, and participated in the establishment of Roche China R&D Center, the first R&D center of a multinational company in Shanghai, bringing the advanced experience, talent concept, technical standards and quality management system of international new drug R&D to China, and contributing to the establishment of the environment of China's biopharmaceutical industry. 

Since founding Hua Medicine in 2010, he has been committed to the research and development of new drugs in the field of diabetes. He has continuously overcome the technical difficulties, filled the domestic gaps, transformed technological advantages into industrial advantages and development momentum, led the company to seize the commanding heights of the future development in diabetes treatment, and achieved significant breakthroughs in the field of Glucokinase Activators (GKA).

Under the leadership of Dr. Li Chen, by applying the concept of blood glucose homeostasis treatment, dorzagliatin (trade name: HuaTangNing), a globally first-in-class, China-first-launch, Class 1 new drug of GKA independently developed by Hua Medicine, was successfully approved for marketing by the National Medical Products Administration (NMPA) in September 2022. This achievement not only introduced a revolutionary treatment modality for diabetes but also plugged a long-standing gap in global GKA research and development. The entire R&D odyssey and the successful market entry of dorzagliatin are a testament not only to Dr. Li Chen's intrepid innovative spirit and unyielding pursuit in scientific exploration but also to the vanguard role played by Chinese innovative drug enterprise managers. 

(Dr. Li Chen gave a speech representing the leading figures at the ceremony)

On the path of innovative R&D, by practicing the model of joint innovation and working closely with enterprises in the industrial chain to share resources, Dr. Li Chen, together with numerous pioneers in innovative drugs, has jointly promoted the prosperous development of the biomedicine industry ecosystem.

Looking to the future, Dr. Li Chen will continue to lead Hua Medicine to move forward on the path of innovation and constantly explore new directions in the field of diabetes treatment. Hua Medicine is actively promoting the development of the second-generation GKA and the fixed combination formulation of dorzagliatin, with the aim of making progress in the fields of personalized diabetes treatment and diabetes complications. The company will also continue to expand the R&D of innovative drugs in the field of metabolic diseases. By utilizing the existing technological accumulation and R&D experience, combine big data and artificial intelligence technology, it will explore more treatment spaces in terms of immune homeostasis and neural homeostasis, bringing more good and new drugs to patients in China and even around the world.

Hua Medicine will also continue to expand the research and development of innovative drugs in the field of metabolic diseases. By leveraging its existing technological accumulation and R&D experience, it will explore more therapeutic possibilities in the aspects of immune homeostasis and neural homeostasis, bringing more excellent and new drugs to patients in China and even around the world. It will make new contributions to promoting scientific and technological innovation, fostering new and high-quality productive forces, and building a modern industrial system.

About Hua Medicine

Hua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing(dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.

For more information

Hua Medicine
Website: www.huamedicine.com
Investors
E-mail: ir@huamedicine.com
Media
Email: pr@huamedicine.com

]]>

Source: Hua Medicine

Copyright 2025 ACN Newswire . All rights reserved.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.